Literature DB >> 24179165

C5a receptor (CD88) blockade protects against MPO-ANCA GN.

Hong Xiao1, Daniel J Dairaghi, Jay P Powers, Linda S Ertl, Trageen Baumgart, Yu Wang, Lisa C Seitz, Mark E T Penfold, Lin Gan, Peiqi Hu, Bao Lu, Norma P Gerard, Craig Gerard, Thomas J Schall, Juan C Jaen, Ronald J Falk, J Charles Jennette.   

Abstract

Necrotizing and crescentic GN (NCGN) with a paucity of glomerular immunoglobulin deposits is associated with ANCA. The most common ANCA target antigens are myeloperoxidase (MPO) and proteinase 3. In a manner that requires activation of the alternative complement pathway, passive transfer of antibodies to mouse MPO (anti-MPO) induces a mouse model of ANCA NCGN that closely mimics human disease. Here, we confirm the importance of C5aR/CD88 in the mediation of anti-MPO-induced NCGN and report that C6 is not required. We further demonstrate that deficiency of C5a-like receptor (C5L2) has the reverse effect of C5aR/CD88 deficiency and results in more severe disease, indicating that C5aR/CD88 engagement enhances inflammation and C5L2 engagement suppresses inflammation. Oral administration of CCX168, a small molecule antagonist of human C5aR/CD88, ameliorated anti-MPO-induced NCGN in mice expressing human C5aR/CD88. These observations suggest that blockade of C5aR/CD88 might have therapeutic benefit in patients with ANCA-associated vasculitis and GN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24179165      PMCID: PMC3904560          DOI: 10.1681/ASN.2013020143

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  23 in total

1.  C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies.

Authors:  Al Carrera-Marín; Z Romay-Penabad; E Papalardo; E Reyes-Maldonado; E García-Latorre; G Vargas; T Shilagard; S Pierangeli
Journal:  Lupus       Date:  2012-08-29       Impact factor: 2.911

2.  Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice.

Authors:  Nirmal K Banda; Stephanie Hyatt; Alexandra H Antonioli; Jason T White; Magdalena Glogowska; Kazue Takahashi; Tod J Merkel; Gregory L Stahl; Stacey Mueller-Ortiz; Rick Wetsel; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2011-12-28       Impact factor: 5.422

3.  Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: a single centre experience.

Authors:  A Gigante; C Salviani; K Giannakakis; E Rosato; B Barbano; A Moroso; M L Gasperini; I Nofroni; F Salsano; R Cianci; F Pugliese
Journal:  Int J Immunopathol Pharmacol       Date:  2012 Jan-Mar       Impact factor: 3.219

Review 4.  Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis.

Authors:  J Charles Jennette; Ronald J Falk; Adil H Gasim
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-05       Impact factor: 2.894

5.  Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.

Authors:  D J Dairaghi; P Zhang; Y Wang; L C Seitz; D A Johnson; S Miao; L S Ertl; Y Zeng; J P Powers; A M Pennell; P Bekker; T J Schall; J C Jaen
Journal:  Clin Pharmacol Ther       Date:  2011-03-30       Impact factor: 6.875

6.  Predominant role for C5b-9 in renal ischemia/reperfusion injury.

Authors:  W Zhou; C A Farrar; K Abe; J R Pratt; J E Marsh; Y Wang; G L Stahl; S H Sacks
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

7.  Genetically determined severity of anti-myeloperoxidase glomerulonephritis.

Authors:  Hong Xiao; Dominic Ciavatta; David L Aylor; Peiqi Hu; Fernando Pardo-Manuel de Villena; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2013-02-04       Impact factor: 4.307

Review 8.  Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.

Authors:  J Charles Jennette; Ronald J Falk; Peiqi Hu; Hong Xiao
Journal:  Annu Rev Pathol       Date:  2013-01-24       Impact factor: 23.472

9.  Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Shen-Ju Gou; Jun Yuan; Min Chen; Feng Yu; Ming-Hui Zhao
Journal:  Kidney Int       Date:  2012-08-22       Impact factor: 10.612

10.  p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation.

Authors:  Jian Hao; Li-Qiang Meng; Peng-Cheng Xu; Min Chen; Ming-Hui Zhao
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

View more
  107 in total

Review 1.  The emerging role of complement inhibitors in transplantation.

Authors:  Véronique Frémeaux-Bacchi; Christophe M Legendre
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

2.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker
Journal:  J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 10.121

3.  With complements from ANCA mice.

Authors:  Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

Review 4.  Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes.

Authors:  Lei Shi
Journal:  Rheumatol Int       Date:  2017-09-27       Impact factor: 2.631

Review 5.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

6.  Treating elderly patients with ANCA-associated vasculitis.

Authors:  J Ashley Jefferson
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-22       Impact factor: 8.237

Review 7.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 8.  Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives.

Authors:  Lucio Manenti; Maria Letizia Urban; Federica Maritati; Maricla Galetti; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

Review 9.  B cell-mediated pathogenesis of ANCA-mediated vasculitis.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

10.  Circulating C3 levels predict renal and global outcome in patients with renal vasculitis.

Authors:  Javier Villacorta; Francisco Diaz-Crespo; Mercedes Acevedo; Teresa Cavero; Carmen Guerrero; Manuel Praga; Gema Fernandez-Juarez
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.